Study Phase Cancer type Number of patients The device, frequency, intensity, and exposure time of TTFields Combining therapy Outcomes Refs
EF-02
Pilot study
rGBM
1
NovoTTF-100A device; Frequence: 100–200 kHz; Field intensity of 0.7 V/cm root mean square (RMS).
-
No response
[110]
EF-07 Pilot clinical trial 10 Not available. - Median time to disease progression: 26.1 weeks; Mean OS: 62.2weeks [21]
EF-11
Randomised phase III clinical trial
TTFields arm: 120; TMZ arm: 117
NovoTTF-100A; Frequence:200 kHz; Field intensity:>0.7 V/cm at the centre of the brain.
-
Mean OS: 6.6 vs 6.0months; Mean PFS: 2.2 vs 2.1months.
[8]
-
Retrospective Study
TMZ/BEV/IRI/TTFields arm:18; BEV/TTFields arm: 30
NovoTTF-100A; Exposure time: >18 hours/ day.
Temozolomide, Bevacizumab, Irinotecan Mean OS: 18.9months; Mean PFS: 10.7months.
[77]

OptimalTTF-1

Pilot study
15
Optune; Frequence:200 kHz; a peak-to-peak current of 1.8–2 A.
Skull remodeling surgery
Mean OS: 15.5 months; Mean PFS: 4.6 months.
[63]
EF-14
Randomised phase III clinical trial
ndGBM
TMZ/TTFields arm:466; TMZ arm: 229
NovoTTF-100A; Frequence: 200 kHz; Exposure time: ≥18 hours/day.
Temozolomide
Mean OS: 19.6 vs 16.6 months; Mean PFS: 7.1 vs 4.0 months.
[9]
-
Retrospective Study
16
Optune; ≥18 hours/day
Temozolomide, Lomustine
Mean PFS: 20months.
[66]
-
Pilot study
30
NovoTTF-200A; Frequence: 200 kHz; Exposure time: ≥18 hours/day.
Concurrent radiotherapy, Temozolomide.
Mean PFS: 9.3 months.
[68]
-
Pilot study
10
NovoTTF-200A; Frequence: 200 kHz; Exposure time: ≥18 hours/day.
Radiotherapy, Temozolomide,
Mean PFS: 8.9 months.
[67]